Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 75, No 2 (2024)
Review paper
Submitted: 2023-08-23
Accepted: 2023-12-07
Published online: 2024-03-05
View PDF Download PDF file
Get Citation

Diabetic gastroparesis: a disease for which long-term therapeutic benefits are difficult to obtain

Jun Zhou12, Sha Li Ran2, Ying Chang Zhao231
DOI: 10.5603/ep.97086
·
Pubmed: 38497371
·
Endokrynol Pol 2024;75(2):148-158.
Affiliations
  1. Southwest Medical University, Luzhou, Sichuan, China
  2. The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China
  3. Department of Endocrinology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China

open access

Vol 75, No 2 (2024)
Review Article
Submitted: 2023-08-23
Accepted: 2023-12-07
Published online: 2024-03-05

Abstract

The pathophysiology of diabetic gastroparesis (DGP), a common complication in diabetic patients, is not fully known. Its development has been linked to several causes, including hyperglycaemia, vagal nerve dysfunction, aberrant Cajal’s interstitial cell network (ICC), lack of nerve nitric oxide synthase (nNOS) expression in the intermuscular plexus, and hormonal alterations in the gastrointestinal tract. Glucose management, diet control, gastric stimulants, anti-emetic medications, Helicobacter pylori eradication, stomach electrical stimulation, and surgery are the main current treatments. These methods, however, could have unfavourable consequences. By examining recent studies and literature reviews, we outline the state of the study on diabetic gastroparesis in this paper.

Abstract

The pathophysiology of diabetic gastroparesis (DGP), a common complication in diabetic patients, is not fully known. Its development has been linked to several causes, including hyperglycaemia, vagal nerve dysfunction, aberrant Cajal’s interstitial cell network (ICC), lack of nerve nitric oxide synthase (nNOS) expression in the intermuscular plexus, and hormonal alterations in the gastrointestinal tract. Glucose management, diet control, gastric stimulants, anti-emetic medications, Helicobacter pylori eradication, stomach electrical stimulation, and surgery are the main current treatments. These methods, however, could have unfavourable consequences. By examining recent studies and literature reviews, we outline the state of the study on diabetic gastroparesis in this paper.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

diabetic gastroparesis; pathogenesis; treatment strategy; adverse effects

About this article
Title

Diabetic gastroparesis: a disease for which long-term therapeutic benefits are difficult to obtain

Journal

Endokrynologia Polska

Issue

Vol 75, No 2 (2024)

Article type

Review paper

Pages

148-158

Published online

2024-03-05

Page views

219

Article views/downloads

32

DOI

10.5603/ep.97086

Pubmed

38497371

Bibliographic record

Endokrynol Pol 2024;75(2):148-158.

Keywords

diabetic gastroparesis
pathogenesis
treatment strategy
adverse effects

Authors

Jun Zhou
Sha Li Ran
Ying Chang Zhao

References (89)
  1. Jalleh RJ, Marathe CS, Jones KL, et al. Digesting the pathogenesis of diabetic gastroparesis. J Diabetes Complications. 2021; 35(10): 107992.
    CrossRefPubMed
  2. Shen S, Xu J, Lamm V, et al. Diabetic Gastroparesis and Nondiabetic Gastroparesis. Gastrointest Endosc Clin N Am. 2019; 29(1): 15–25.
    CrossRefPubMed
  3. Sangnes DA, Søfteland E, Teigland T, et al. Comparing radiopaque markers and C-labelled breath test in diabetic gastroparesis diagnostics. Clin Exp Gastroenterol. 2019; 12: 193–201.
    CrossRefPubMed
  4. Dilmaghani S, Zheng T, Camilleri M. Epidemiology and Healthcare Utilization in Patients With Gastroparesis: A Systematic Review. Clin Gastroenterol Hepatol. 2023; 21(9): 2239–2251.e2.
    CrossRefPubMed
  5. Syed AR, Wolfe MM, Calles-Escandon J. Epidemiology and Diagnosis of Gastroparesis in the United States: A Population-based Study. J Clin Gastroenterol. 2020; 54(1): 50–54.
    CrossRefPubMed
  6. Huang IH, Schol J, Carbone F, et al. Worldwide prevalence and burden of gastroparesis-like symptoms as defined by the United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European Gastroenterol J. 2022; 10(8): 888–897.
    CrossRefPubMed
  7. Tanner SE, Burton Murray H, Brown TA, et al. Gastrointestinal-Specific symptom anxiety in patients with gastroparesis: Relationships to symptom severity and quality of life. Neurogastroenterol Motil. 2023; 35(5): e14534.
    CrossRefPubMed
  8. Cherian D, Sachdeva P, Fisher RS, et al. Abdominal pain is a frequent symptom of gastroparesis. Clin Gastroenterol Hepatol. 2010; 8(8): 676–681.
    CrossRefPubMed
  9. Longley KJ, Ho V. Practical management approach to gastroparesis. Intern Med J. 2020; 50(8): 909–917.
    CrossRefPubMed
  10. Chikkamenahalli LL, Pasricha PJ, Farrugia G, et al. Gastric Biopsies in Gastroparesis: Insights into Gastric Neuromuscular Disorders to Aid Treatment. Gastroenterol Clin North Am. 2020; 49(3): 557–570.
    CrossRefPubMed
  11. Tseng PH, Chao CC, Cheng YY, et al. Diabetic visceral neuropathy of gastroparesis: Gastric mucosal innervation and clinical significance. Eur J Neurol. 2022; 29(7): 2097–2108.
    CrossRefPubMed
  12. Usai-Satta P, Bellini M, Morelli O, et al. Gastroparesis: New insights into an old disease. World J Gastroenterol. 2020; 26(19): 2333–2348.
    CrossRefPubMed
  13. Coleski R, Hasler WL. Coupling and propagation of normal and dysrhythmic gastric slow waves during acute hyperglycaemia in healthy humans. Neurogastroenterol Motil. 2009; 21(5): 492–9, e1.
    CrossRefPubMed
  14. Halland M, Bharucha AE. Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus. Clin Gastroenterol Hepatol. 2016; 14(7): 929–936.
    CrossRefPubMed
  15. Sullivan A, Temperley L, Ruban A. Pathophysiology, Aetiology and Treatment of Gastroparesis. Dig Dis Sci. 2020; 65(6): 1615–1631.
    CrossRefPubMed
  16. Meldgaard T, Olesen SS, Farmer AD, et al. Diabetic Enteropathy: From Molecule to Mechanism-Based Treatment. J Diabetes Res. 2018; 2018: 3827301.
    CrossRefPubMed
  17. Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil. 2014; 26(5): 611–624.
    CrossRefPubMed
  18. Huang Ju. Analysis of the Relationship between Infection and Diabetic Gastroparesis. Chin Med J (Engl). 2017; 130(22): 2680–2685.
    CrossRefPubMed
  19. Nguyen L, Wilson LA, Miriel L, et al. NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Autonomic function in gastroparesis and chronic unexplained nausea and vomiting: Relationship with etiology, gastric emptying, and symptom severity. Neurogastroenterol Motil. 2020; 32(8): e13810.
    CrossRefPubMed
  20. Steinsvik EK, Sangnes DA, Søfteland E, et al. Gastric function in diabetic gastroparesis assessed by ultrasound and scintigraphy. Neurogastroenterol Motil. 2022; 34(4): e14235.
    CrossRefPubMed
  21. Eckersley L. Role of the Schwann cell in diabetic neuropathy. Int Rev Neurobiol. 2002; 50: 293–321.
    CrossRefPubMed
  22. Brock C, Graversen C, Frøkjaer JB, et al. Peripheral and central nervous contribution to gastrointestinal symptoms in diabetic patients with autonomic neuropathy. Eur J Pain. 2013; 17(6): 820–831.
    CrossRefPubMed
  23. Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019; 68(12): 2238–2250.
    CrossRefPubMed
  24. Meldgaard T, Keller J, Olesen AE, et al. Pathophysiology and management of diabetic gastroenteropathy. Therap Adv Gastroenterol. 2019; 12: 1756284819852047.
    CrossRefPubMed
  25. Modi S, Syed Gaggatur N, Sange AH, et al. An Emerging Facet of Diabetes Mellitus: The Nexus of Gastrointestinal Disorders. Cureus. 2021; 13(9): e18245.
    CrossRefPubMed
  26. Camilleri M, Camilleri M, Bharucha AE. Gastrointestinal dysfunction in neurologic disease. Semin Neurol. 1996; 16(3): 203–216.
    CrossRefPubMed
  27. Horváth VJ, Vittal H, Lörincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology. 2006; 130(3): 759–770.
    CrossRefPubMed
  28. Singh R, Ha SeE, Wei L, et al. miR-10b-5p Rescues Diabetes and Gastrointestinal Dysmotility. Gastroenterology. 2021; 160(5): 1662–1678.e18.
    CrossRefPubMed
  29. Choi KM, Gibbons SJ, Nguyen TV, et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 2008. 2008; 135(6): 2055–2064.
    CrossRefPubMed
  30. Ward SM. Hyperplasia of Interstitial Cells of Cajal Leads to Rapid Gastric Emptying in Diabetes. Gastroenterology. 2017; 153(2): 350–352.
    CrossRefPubMed
  31. Cipriani G, Gibbons SJ, Miller KE, et al. Change in Populations of Macrophages Promotes Development of Delayed Gastric Emptying in Mice. Gastroenterology. 2018; 154(8): 2122–2136.e12.
    CrossRefPubMed
  32. Yarandi SS, Kulkarni S, Saha M, et al. ntestinal Bacteria Maintain Adult Enteric Nervous System and Nitrergic Neurons via Toll-like Receptor 2-induced Neurogenesis in Mice. Gastroenterology. 2020; 159(1): 200–213.
    CrossRefPubMed
  33. Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest. 2000; 106(3): 373–384.
    CrossRefPubMed
  34. Idrizaj E, Nistri S, Zizi V, et al. Neuronal Nitric Oxide Synthase as a Shared Target for the Effects of Adiponectin and Resistin on the Mechanical Responses of the Mouse Gastric Fundus. Int J Mol Sci. 2022; 23(24).
    CrossRefPubMed
  35. Guerra DD, Bok R, Lorca RA, et al. Akt phosphorylation of neuronal nitric oxide synthase regulates gastrointestinal motility in mouse ileum. Proc Natl Acad Sci U S A. 2019; 116(35): 17541–17546.
    CrossRefPubMed
  36. Kashyap P, Farrugia G. Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years. Gut. 2010; 59(12): 1716–1726.
    CrossRefPubMed
  37. Sampath C, Raju AV, Freeman ML, et al. Nrf2 attenuates hyperglycemia-induced nNOS impairment in adult mouse primary enteric neuronal crest cells and normalizes stomach function. Am J Physiol Gastrointest Liver Physiol. 2022; 322(3): G368–G382.
    CrossRefPubMed
  38. Sampath C, Sprouse JC, Freeman ML, et al. Activation of Nrf2 attenuates delayed gastric emptying in obesity induced diabetic (T2DM) female mice. Free Radic Biol Med. 2019; 135: 132–143.
    CrossRefPubMed
  39. Guerra DD, Bok R, Lorca RA, et al. Protein kinase A facilitates relaxation of mouse ileum via phosphorylation of neuronal nitric oxide synthase. Br J Pharmacol. 2020; 177(12): 2765–2778.
    CrossRefPubMed
  40. Petri M, Singh I, Baker C, et al. Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. J Diabetes Complications. 2021; 35(2): 107733.
    CrossRefPubMed
  41. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019; 30: 72–130.
    CrossRefPubMed
  42. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018; 27(4): 740–756.
    CrossRefPubMed
  43. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6): 2131–2157.
    CrossRefPubMed
  44. Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest. 1996; 97(1): 92–103.
    CrossRefPubMed
  45. Steinert RE, Feinle-Bisset C, Asarian L, et al. Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. Physiol Rev. 2017; 97(1): 411–463.
    CrossRefPubMed
  46. Higham A, Vaillant C, Yegen B, et al. Relation between cholecystokinin and antral innervation in the control of gastric emptying in the rat. Gut. 1997; 41(1): 24–32.
    CrossRefPubMed
  47. Parkman HP, Sharkey E, McCallum RW, et al. NIH/NIDDK Gastroparesis Consortium. Constipation in Patients With Symptoms of Gastroparesis: Analysis of Symptoms and Gastrointestinal Transit. Clin Gastroenterol Hepatol. 2022; 20(3): 546–558.e5.
    CrossRefPubMed
  48. El Halabi M, Parkman HP. 2023 update on the clinical management of gastroparesis. Expert Rev Gastroenterol Hepatol. 2023; 17(5): 431–441.
    CrossRefPubMed
  49. Seabrook N, Kedar A, Bills G, et al. Inflammatory Markers and Mortality in Diabetic Versus Idiopathic Gastroparesis. Am J Med Sci. 2022; 363(3): 218–223.
    CrossRefPubMed
  50. Bonetto S, Gruden G, Beccuti G, et al. Management of Dyspepsia and Gastroparesis in Patients with Diabetes. A Clinical Point of View in the Year 2021. J Clin Med. 2021; 10(6).
    CrossRefPubMed
  51. Sangnes DA, Søfteland E, Bekkelund M, et al. Wireless motility capsule compared with scintigraphy in the assessment of diabetic gastroparesis. Neurogastroenterol Motil. 2020; 32(4): e13771.
    CrossRefPubMed
  52. Lee AA, Rao S, Nguyen LA, et al. Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis. Clin Gastroenterol Hepatol. 2019; 17(9): 1770–1779.e2.
    CrossRefPubMed
  53. Soliman H, Gourcerol G. Targeting the pylorus in gastroparesis: From physiology to endoscopic pyloromyotomy. Neurogastroenterol Motil. 2023; 35(2): e14529.
    CrossRefPubMed
  54. Navas CM, Patel NK, Lacy BE. Symptomatic Management of Gastroparesis. Gastrointest Endosc Clin N Am. 2019; 29(1): 55–70.
    CrossRefPubMed
  55. Shakhatreh M, Jehangir A, Malik Z, et al. Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol. 2019; 13(8): 711–721.
    CrossRefPubMed
  56. Sarosiek I, Van Natta M, Parkman HP, et al. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Gastroparesis Clinical Research Consortium (GpCRC). Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium. Clin Gastroenterol Hepatol. 2022; 20(3): e452–e464.
    CrossRefPubMed
  57. Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study. Am J Gastroenterol. 2019; 114(8): 1265–1274.
    CrossRefPubMed
  58. Hong SW, Chun J, Kim J, et al. Efficacy and Safety of Ghrelin Agonists in Patients with Diabetic Gastroparesis: A Systematic Review and Meta-Analysis. Gut Liver. 2020; 14(5): 589–600.
    CrossRefPubMed
  59. Smieszek SP, Carlin JL, Xiao C, et al. Enrichment of Motilin Receptor Loss-of-Function Variants in Gastroparesis. Clin Transl Gastroenterol. 2022; 13(4): e00474.
    CrossRefPubMed
  60. Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am. 2015; 44(1): 97–111.
    CrossRefPubMed
  61. Szeto L, Yazdian A, Parkman HP. Atypical Causes of Gastroparesis: Prevalence, Gastric Emptying, and Clinical Features. J Clin Gastroenterol. 2023; 57(9): 895–900.
    CrossRefPubMed
  62. Youssef AS, Parkman HP, Nagar S. Drug-drug interactions in pharmacologic management of gastroparesis. Neurogastroenterol Motil. 2015; 27(11): 1528–1541.
    CrossRefPubMed
  63. Hasler WL. Symptomatic management for gastroparesis: antiemetics, analgesics, and symptom modulators. Gastroenterol Clin North Am. 2015; 44(1): 113–126.
    CrossRefPubMed
  64. Malamood M, Roberts A, Kataria R, et al. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017; 11: 1035–1041.
    CrossRefPubMed
  65. Lacy BE, Saito YA, Camilleri M, et al. Effects of Antidepressants on Gastric Function in Patients with Functional Dyspepsia. Am J Gastroenterol. 2018; 113(2): 216–224.
    CrossRefPubMed
  66. Tack J, Masuy I, Van Den Houte K, et al. Drugs under development for the treatment of functional dyspepsia and related disorders. Expert Opin Investig Drugs. 2019; 28(10): 871–889.
    CrossRefPubMed
  67. Igarashi M, Nakae H, Matsuoka T, et al. Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia. BMJ Open Gastroenterol. 2017; 4(1): e000144.
    CrossRefPubMed
  68. Jehangir A, Parkman HP. Cannabinoid Use in Patients With Gastroparesis and Related Disorders: Prevalence and Benefit. Am J Gastroenterol. 2019; 114(6): 945–953.
    CrossRefPubMed
  69. Goldney J, Sargeant JA, Davies MJ. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia. 2023; 66(10): 1832–1845.
    CrossRefPubMed
  70. De Fano M, Porcellati F, Fanelli CG, et al. The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime? Diabetes Res Clin Pract. 2023; 203: 110828.
    CrossRefPubMed
  71. Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014; 63(2): 785–790.
    CrossRefPubMed
  72. Jelsing J, Vrang N, Hansen G, et al. Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight. Diabetes Obes Metab. 2012; 14(6): 531–538.
    CrossRefPubMed
  73. Flint A, Kapitza C, Hindsberger C, et al. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011; 28(3): 213–226.
    CrossRefPubMed
  74. Drucker DJ, Buse JB, Taylor K, et al. DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008; 372(9645): 1240–1250.
    CrossRefPubMed
  75. Beti C, Stratmann B, Bokman G, et al. Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions. Horm Metab Res. 2019; 51(4): 267–273.
    CrossRefPubMed
  76. Kim D, Gedney R, Allen S, et al. Does etiology of gastroparesis determine clinical outcomes in gastric electrical stimulation treatment of gastroparesis? Surg Endosc. 2021; 35(8): 4550–4554.
    CrossRefPubMed
  77. Zoll B, Jehangir A, Edwards MA, et al. Gastric Electric Stimulation for Refractory Gastroparesis. J Clin Outcomes Manag. 2019; 26(1): 27–38.
    PubMed
  78. Abell TL, Van Cutsem E, Abrahamsson H, et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion. 2002; 66(4): 204–212.
    CrossRefPubMed
  79. McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol. 2010; 8(11): 947–54; quiz e116.
    CrossRefPubMed
  80. Rajamanuri M, Mannava SM, Chhabra J, et al. A Systematic Review of the Therapeutic Role of Gastric Pacemakers in Adults With Gastroparesis. Cureus. 2021; 13(9): e18152.
    CrossRefPubMed
  81. Marowski S, Xu Y, Greenberg JA, et al. Both gastric electrical stimulation and pyloric surgery offer long-term symptom improvement in patients with gastroparesis. Surg Endosc. 2021; 35(8): 4794–4804.
    CrossRefPubMed
  82. Al-Saffar A, Lennernäs H, Hellström PM. Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. Neurogastroenterol Motil. 2019; 31(11): e13617.
    CrossRefPubMed
  83. Lai CH, Yeh YC, Chen YY. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019; 10: 2042098619854007.
    CrossRefPubMed
  84. Camilleri M, Lembo A, McCallum R, et al. Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. Aliment Pharmacol Ther. 2020; 51(11): 1139–1148.
    CrossRefPubMed
  85. Landreneau JP, Strong AT, El-Hayek K, et al. Laparoscopic pyloroplasty versus endoscopic per-oral pyloromyotomy for the treatment of gastroparesis. Surg Endosc. 2019; 33(3): 773–781.
    CrossRefPubMed
  86. Samaan JS, Toubat O, Alicuben ET, et al. Gastric electric stimulator versus gastrectomy for the treatment of medically refractory gastroparesis. Surg Endosc. 2022; 36(10): 7561–7568.
    CrossRefPubMed
  87. Labonde A, Lades G, Debourdeau A, et al. Gastric peroral endoscopic myotomy in refractory gastroparesis: long-term outcomes and predictive score to improve patient selection. Gastrointest Endosc. 2022; 96(3): 500–508.e2.
    CrossRefPubMed
  88. Abdelfatah MM, Noll A, Kapil N, et al. Short-term outcomes of double versus single pyloromyotomy at peroral endoscopic pyloromyotomy in the treatment of gastroparesis (with video). Gastrointest Endosc. 2020; 92(3): 603–609.
    CrossRefPubMed
  89. Mekaroonkamol P, Patel V, Shah R, et al. Association between duration or etiology of gastroparesis and clinical response after gastric per-oral endoscopic pyloromyotomy. Gastrointest Endosc. 2019; 89(5): 969–976.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl